Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis

References

• Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378–1388.
   PubMed Web of Science ®Google Scholar
• Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev. 2007;31(1):52–63.
   PubMed Web of Science ®Google Scholar
• Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282(8):417–420.
   PubMed Web of Science ®Google Scholar
• De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. Jama. 2001;285(2):177–181.
   PubMed Web of Science ®Google Scholar
• Dellicour S, Greenwood B. Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health. 2007;12(12):1409–1421.
   PubMed Web of Science ®Google Scholar
• Kelly DF, Snape MD, Clutterbuck EA, et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood. 2006;108(8):2642–2647.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Stuart JM, Group UKMC. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829–1831.
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58–S67.
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Bmj. 2003;326(7385):365–366.
   PubMed Web of Science ®Google Scholar
• Gjini AB, Stuart JM, Lawlor DA, et al. Changing epidemiology of bacterial meningitis among adults in England and Wales 1991-2002. Epidemiol Infect. 2006;134(3):567–569.
   PubMed Web of Science ®Google Scholar
• McIntyre PB, O’Brien KL, Greenwood B, et al. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012;380(9854):1703–1711.
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840–847.
   PubMed Web of Science ®Google Scholar
• Bijlsma MW, Bekker V, Brouwer MC, et al. Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data. Lancet Infect Dis. 2014;14(9):805–812.
   PubMed Web of Science ®Google Scholar
• Ali A, Jafri RZ, Messonnier N, et al. Global practices of meningococcal vaccine use and impact on invasive disease. Pathog Glob Health. 2014;108(1):11–20.
   PubMed Web of Science ®Google Scholar
• Cardoso CW, Ribeiro GS, Reis MG, et al. Effectiveness of meningococcal C conjugate vaccine in salvador, Brazil: a case-control study. PLoS One. 2015;10(4):e0123734.
   Google Scholar
• European Centre for Disease Prevention and Control. Vaccine Schedule [Internet]. 2015. [cited 2015 Aug 9]. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
   Google Scholar
• World Health Organization. Immunization schedules by antigens [Internet]. 2015. [cited 2015 Aug 9]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules
   Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23(17–18):2222–2227.
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69(3):1568–1573.
   PubMed Web of Science ®Google Scholar
• Lakshman R, Finn A. Meningococcal serogroup C conjugate vaccine. Expert Opin Biol Ther. 2002;2(1):87–96.
   PubMed Web of Science ®Google Scholar
• Serogroup C. Meningococcal conjugate vaccines: new preparations. Effective from age two months. Prescrire Int. 2003;12(64):43–46.
   PubMedGoogle Scholar
• Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine. 2001;19(20–22):2924–2931.
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002;186(9):1353–1357.
   PubMed Web of Science ®Google Scholar
• English M, MacLennan JM, Bowen-Morris JM, et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine. 2000;19(9–10):1232–1238.
   PubMed Web of Science ®Google Scholar
• Collins CL, Ruggeberg JU, Balfour G, et al. Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants. Pediatr Infect Dis J. 2005;24(11):966–968.
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999;179(6):1569–1572.
   PubMed Web of Science ®Google Scholar
• Slack MH, Schapira D, Thwaites RJ, et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis. 2001;184(12):1617–1620.
   PubMed Web of Science ®Google Scholar
• Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J. 2001;20(2):153–159.
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183(1):160–163.
   PubMed Web of Science ®Google Scholar
• Burrage M, Robinson A, Borrow R, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun. 2002;70(9):4946–4954.
   PubMed Web of Science ®Google Scholar
• Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181(2):761–764.
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N, et al. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis. 2001;184(3):377–380.
   PubMed Web of Science ®Google Scholar
• Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009;28(4 Suppl):S97–S108.
   PubMed Web of Science ®Google Scholar
• Pace D, Snape M, Westcar S, et al. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pediatr Infect Dis J. 2007;26(11):1057–1059.
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2006;25(8):713–720.
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Omenaca F, Garcia-Sicilia J, et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2004;23(12):1109–1115.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine. 2010;28(32):5272–5279.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bianco V, et al. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine. 2011;29(25):4274–4284.
   PubMed Web of Science ®Google Scholar
• Booy R, Richmond P, Nolan T, et al. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. Pediatr Infect Dis J. 2011;30(4):340–342.
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Cantarino MV, Torrenti JM, et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29(2):148–152.
   PubMed Web of Science ®Google Scholar
• Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol. 2009;16(2):194–199.
   PubMed Web of Science ®Google Scholar
• Pace D, Khatami A, McKenna J, et al. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. Bmj. 2015;350:h1554.
   Google Scholar
• Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17(1):154–159.
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Moro M, Merino JM, et al. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis J. 2008;27(7):579–588.
   PubMed Web of Science ®Google Scholar
• Pace D, Snape M, Westcar S, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child. 2008;93(11):963–970.
   PubMed Web of Science ®Google Scholar
• Khatami A, Peters A, Robinson H, et al. Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood. Clin Vaccine Immunol. 2011;18(12):2038–2042.
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Green B, et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24(2):128–131.
   PubMed Web of Science ®Google Scholar
• Perrett KP, Richmond PC, Borrow R, et al. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination. Pediatr Infect Dis J. 2015;34(3):279–285.
   PubMed Web of Science ®Google Scholar
• Ishola DA, Andrews N, Waight P, et al. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age. Pediatr Infect Dis J. 2015;34(8):865–874.
   PubMed Web of Science ®Google Scholar
• Borrow R, Longworth E, Gray SJ, et al. Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom. FEMS Immunol Med Microbiol. 2000;28(3):189–191.
   PubMed Web of Science ®Google Scholar
• Arakere G, Frasch CE. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect Immun. 1991;59(12):4349–4356.
   PubMed Web of Science ®Google Scholar
• Glode MP, Lewin EB, Sutton A, et al. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J Infect Dis. 1979;139(1):52–59.
   PubMed Web of Science ®Google Scholar
• Steinhoff MC, Lewin EB, Gotschlich EC, et al. Group C Neisseria meningitidis variant polysaccharide vaccines in children. Infect Immun. 1981;34(1):144–146.
   PubMed Web of Science ®Google Scholar
• Fusco PC, Farley EK, Huang CH, et al. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin Vaccine Immunol. 2007;14(5):577–584.
   PubMed Web of Science ®Google Scholar
• Pichichero M, Anderson P, Gotschlich E, et al. Immunogenicity of O-acetyl-negative and -positive polysaccharide vaccines for infections with Neisseria meningitidis group C in infants. J Infect Dis. 1985;152(4):850–851.
   PubMed Web of Science ®Google Scholar
• Ho MM, Bolgiano B, Corbel MJ. Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines. Vaccine. 2000;19(7–8):716–725.
   PubMed Web of Science ®Google Scholar
• Sakou II, Tzanakaki G, Tsolia MN, et al. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine. 2009;27(33):4408–4411.
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. Bmj. 2008;336(7659):1487–1491.
   PubMed Web of Science ®Google Scholar
• Garside P, Ingulli E, Merica RR, et al. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 1998;281(5373):96–99.
   PubMed Web of Science ®Google Scholar
• Paus D, Phan TG, Chan TD, et al. Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. J Exp Med. 2006;203(4):1081–1091.
   PubMed Web of Science ®Google Scholar
• Khatami A, Clutterbuck EA, Thompson AJ, et al. Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines–exploratory analyses within a randomised controlled trial. PLoS One. 2014;9(7):e101672.
   Google Scholar
• Blanchard Rohner G, Snape MD, Kelly DF, et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol. 2008;180(4):2165–2173.
   PubMed Web of Science ®Google Scholar
• Khatami A, Snape MD, Wysocki J, et al. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study. Pediatr Infect Dis J. 2012;31(10):1069–1073.
   PubMed Web of Science ®Google Scholar
• Kitchin NR, Southern J, Morris R, et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child. 2007;92(1):11–16.
   PubMed Web of Science ®Google Scholar
• Pollabauer EM, Petermann R, Ehrlich HJ. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine. 2009;27(11):1674–1679.
   PubMed Web of Science ®Google Scholar
• Dagan R, Eskola J, Leclerc C, et al. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun. 1998;66(5):2093–2098.
   PubMed Web of Science ®Google Scholar
• Khatami A, Snape MD, Ohene-Kena B, et al. Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants. Pediatr Infect Dis J. 2013;32(6):675–681.
   PubMed Web of Science ®Google Scholar
• Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine. 2011;29(31):4881–4890.
   PubMed Web of Science ®Google Scholar
• McVernon J, Maclennan J, Buttery J, et al. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J. 2002;21(8):747–753.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187–195.
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357(9251):195–196.
   PubMed Web of Science ®Google Scholar
• Bose A, Coen P, Tully J, et al. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet. 2003;361(9358):675–676.
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, Garcia M, et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23(32):4097–4100.
   PubMed Web of Science ®Google Scholar
• Garrido-Estepa M, Leon-Gomez I, Herruzo R, et al. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. Vaccine. 2014;32(22):2604–2609.
   PubMed Web of Science ®Google Scholar
• Borrow R, Southern J, Andrews N, et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine. 2001;19(23–24):3043–3050.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–220.
   PubMed Web of Science ®Google Scholar